Precision Therapeutics (NASDAQ:POAI) is scheduled to announce its earnings results after the market closes on Monday, August 19th.

Precision Therapeutics (NASDAQ:POAI) last announced its earnings results on Wednesday, May 15th. The medical instruments supplier reported ($0.21) earnings per share (EPS) for the quarter. The business had revenue of $0.26 million for the quarter. Precision Therapeutics had a negative net margin of 925.08% and a negative return on equity of 714.98%.

Shares of NASDAQ POAI opened at $0.57 on Friday. The company has a debt-to-equity ratio of 3.68, a quick ratio of 0.71 and a current ratio of 0.77. Precision Therapeutics has a 12-month low of $0.40 and a 12-month high of $1.26.

In other Precision Therapeutics news, CEO Carl I. Schwartz bought 100,000 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were purchased at an average cost of $0.56 per share, for a total transaction of $56,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 13.38% of the stock is currently owned by corporate insiders.

Precision Therapeutics Company Profile

Predictive Oncology Inc provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables.

Recommended Story: SEC Filing

Earnings History for Precision Therapeutics (NASDAQ:POAI)

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.